Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial
Published in:
Transfuze Hematol. dnes,21, 2015, No. 1, p. 46.
Category:
Selection of press reports and books
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2015 Issue 1
- What FVIII Levels Are Ideal for Preventing Bleeding in Hemophilia A?
- Administration of aPCC as a Prevention of Bleeding After Major Cardiac Surgical Procedures
- Cost Effectiveness of FVIII Substitution Versus Non-Factor Therapy for Hemophilia A
- Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?
- Prognostic Significance of Subclinical Joint Changes on MRI in Hemophilia
Most read in this issue
- Infectious complications of induction therapy in acute myeloid leukaemia patients without the use of antibiotic prophylaxis
- Interference of blood plasma components in turbidimetric D-dimer estimation
- Invasive fungal infections following autologous hematopoietic stem cell transplantation in patients with multiple myeloma
- Engraftment of acute and chronic myeloid leukemia in NOD scid gamma mice